Why does Regorafenib (Belvango) adopt a 21-day on-take and 7-day-off cycle and analysis of the reasons

Regorafenib is an oral multi-target tyrosine kinase inhibitor (TKI) that is widely used to treat advanced colorectal cancer, gastrointestinal stromal tumors (GIST), and hepatocellular carcinoma. Its standard medication regimen adopts a 21 days of continuous administration followed by a 7 day cycle (21 day /28 day cycle). This design is mainly to balance drug efficacy and safety and ensure patient tolerance in long-term treatment.

Regofenib has a long half-life and cumulative toxicity. During continuous medication, the drug gradually reaches a steady-state blood concentration in the body, which can fully inhibit cancer cell proliferation and angiogenesis. However, long-term continuous exposure to high concentrations may lead to accumulation of adverse reactions, such as hand-foot syndrome, liver function abnormalities, hypertension and fatigue. Therefore, setting up a 7 -day withdrawal period after taking 21 days can allow the drug concentration in the body to gradually decrease and provide recovery time for the patient's liver, skin and other organs.

21The cycle design of 21 days is closely related to the clinical trial data. In key clinical studies (such as the CORRECT and CONCUR trials), the regimen of 21/7 cycles can maintain effective tumor suppression while minimizing the incidence of serious adverse reactions. During the drug withdrawal period, patients can regain physical strength, adjust blood pressure and liver function indicators, and prepare for the next cycle of continuous treatment, thereby achieving long-term sustainable treatment.

This periodic administration also facilitates clinical management of adverse reactions. If the patient experiences moderate or severe side effects within 21 days, the doctor can alleviate the symptoms by extending the withdrawal time, adjusting the dose, or using symptomatic treatment without affecting the efficacy of the overall treatment. Through this periodic dosing model, regorafenib improves patients' medication compliance and quality of life while ensuring the anti-tumor effect.

Reference link:https://www.drugs.com